GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - NEWAMSTERDAM PHARMA CO NV

Financial Performance:

• No specific financial metrics (revenue, earnings, margins, cash flow, debt) were disclosed in the transcript as the company is in a clinical development phase prior to commercial launch.
• Commercial launch of OB (obecetrapib) and OB Easy (fixed-dose combination with ezetimide) is scheduled in Germany by the end of the year, marking the transition to a commercial reality.

Guidance and Future Outlook:

• Clinical Milestones: The PREVAIL study interim analysis is expected to be triggered by the end of the current year, with Data Safety Monitoring Board (DSMB) feedback anticipated in Q1 of next year.
• Pipeline Timeline: Completion of remaining cardiovascular studies (Rubens) and the PREVAIL final analysis is projected for the end of next year; the Rembrandt imaging trial is expected to conclude toward the end of next year.
• Regulatory Strategy: If the interim analysis is positive, an NDA submission will occur immediately. Approximately 90% of the US and EU application data is already prepared. Filing timing for a full trial completion will be discussed with the FDA.

Business Segments and Product Lines:

• Obecetrapib (OB): A CETP inhibitor showing potential to reduce LDL-C; launched in Europe (Germany) alongside ezetimide (OB Easy).
• Differentiation Strategy: Highlights a ~15% reduction in new-onset diabetes risk compared to high-intensity statins (which can increase diabetes risk by up to 36% in some populations).
• Product Portfolio: Offering both single-entity OB and a fixed-dose combination with ezetimide to achieve aggressive LDL-C lowering targets.
• Upcoming Studies:
  • Rubens: Targeting patients with Type 2 diabetes/metabolic syndrome without prior ASCVD events.
  • Rembrandt: An imaging trial assessing plaque stabilization/clearance for the fixed-dose combination.

Market and Competitive Landscape:

• Lp(a) Focus: Following the neutral Horizon study results for LP(la) inhibitors, the market consensus remains that Lp(a) is an independent risk factor; the strategy emphasizes aggressive LDL-C lowering which mitigates Lp(a) risk.
• Statins & PCSK9s: Positions OB as a differentiation point against statins (diabetes risk mitigation) and PCSK9s (limited to LDL reduction).
• Competitive Context: Discusses the failure of prior CETP inhibitors (e.g., Anacetrapib/REVEAL) and AcCELERATE (Evacetrapib) due to study design flaws (direct LDL measurement overstatement, short duration) rather than drug efficacy, contrasting with the current robust study design.

Risks and Challenges:

• Clinical Outcome Risk: Despite optimism based on blinded data and the "Broadway" mini-study, there is inherent statistical risk; the company acknowledges that hitting one MACE endpoint (MACE3) but missing the other (MACE4) could cause the trial to continue.
• Study Continuation: Potential for the trial to proceed past the interim analysis if strict statistical thresholds are not met at that specific juncture.
• Market Adoption: Reliance on physicians accepting the Lp(a) narrative and the need for branded therapies to achieve lowest possible LDL targets.

Management Commentary and Tone:

• Tone: Optimistic yet cautious; management expresses high confidence in the drug's potential but avoids specific statistical predictions to prevent misinterpretation of early signals.
• Confidence: Leadership asserts they would not have initiated an interim analysis without believing there was a meaningful chance of success.
• Strategic Clarity: Emphasizes the value of delivering clinical outcome data at launch to drive physician adoption and peer access.

Analyst Questions and Answers:

• Question on Horizon Data: Analysts asked about the neutral Lp(a) inhibitor results. Management responded that while disappointing for the class, the data reinforced the need for aggressive LDL-C lowering and that Lp(a) remains a key driver of risk that cannot be ignored.
• Question on MACE Thresholds: Analysts requested specific MACE3/MACE4 thresholds for the interim. Management declined to provide exact numbers, citing the statistical infallibility risk, but confirmed the study is well-powered based on Broadway-like effects.
• Question on Event Rate Slowdown: Analysts asked about the "slowdown" in event rates in blinded data. Management attributed this to a true drug effect rather than improved standard of care or drop-in rates (GLP-1/SGLT2), citing the "Broadway" roadmap as validation.
• Question on ACCELERATE Study: Analysts queried why the negative Evacetrapib (Accelerate) trial doesn't invalidate PREVAIL. Management cited methodological differences (direct vs. beta-quant LDL measurement) and insufficient study duration in the competitor trial.

Other Key Points:

• Study Design Validation: Management drew strong parallels between the PREVAIL study design and the successful "Broadway" study, noting similar patient populations and adjudication committees.
• Lp(a) Threshold Unknown: It remains unclear if there is a specific Lp(a) threshold required to see MACE benefits, though trends suggest patients with higher baseline Lp(a) and LDL benefited most in prior data.
• Diabetes Benefit: The ability to offset statin-induced diabetes risk while lowering LDL is highlighted as a critical unique selling proposition (USP) for clinician adoption.